BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 22415461)

  • 41. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.
    Palanisamy N; Tsodikov A; Yan W; Suleman K; Rittmaster R; Lucia SM; Chinnaiyan AM; Fleshner N; Kunju LP
    Urol Oncol; 2015 Mar; 33(3):108.e5-13. PubMed ID: 25175425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
    Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
    J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
    Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
    Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
    Masoodi KZ; Ramos Garcia R; Pascal LE; Wang Y; Ma HM; O'Malley K; Eisermann K; Shevrin DH; Nguyen HM; Vessella RL; Nelson JB; Parikh RA; Wang Z
    Endocrinology; 2013 Jul; 154(7):2296-307. PubMed ID: 23671262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
    Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
    Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.
    Schmidt LJ; Regan KM; Anderson SK; Sun Z; Ballman KV; Tindall DJ
    Prostate; 2009 Dec; 69(16):1730-43. PubMed ID: 19676081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
    Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
    J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
    Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
    PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
    Cai C; Wang H; Xu Y; Chen S; Balk SP
    Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.
    Lehmusvaara S; Erkkilä T; Urbanucci A; Jalava S; Seppälä J; Kaipia A; Kujala P; Lähdesmäki H; Tammela TL; Visakorpi T
    Prostate; 2013 Jan; 73(1):101-12. PubMed ID: 22674191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL
    PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
    Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
    Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ETS fusion genes in prostate cancer.
    Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
    Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
    Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
    Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.